

Galápagos

Q1 Results 2018

Webcast presentation | 26 April 2018



Disclaimer

This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the slides captioned "Ph3 program ISABELA 1&2," "FALCON," "2018 outlook," statements regarding the development of the triple combination therapy cystic fibrosis program, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (i) with filgotinib in rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, and other potential indications, (ii) in the cystic fibrosis program, including the development of triple combination therapies, (iii) with GLPG1690 and GLPG1205 in idiopathic pulmonary arthritis, (iv) with GLPG1972 in osteoarthritis, (v) with MOR106 in atopic dermatitis, and expectations regarding the commercial potential of our product candidates and our investment in our commercial capabilities. When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "possible," "predict," "objective," "should," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons), reliance on third parties (including Galapagos' collaboration partners AbbVie, Gilead, Servier and MorphoSys) and estimating the commercial potential of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission ("SEC") filing and reports, including Galapagos' most recent Form 20-F filing for the year ended December 31, 2017, and subsequent reports filed by Galapagos with the SEC. Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements.

All statements contained herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation.



Q1 2018 Results

- **Q1 highlights/outlook**

Onno van de Stolpe, CEO

Bart Filius, COO & CFO

- Q & A

Onno, Bart

Walid Abi-Saab, CMO

Piet Wigerinck, CSO



Delivery in Q1 2018

Inflammation

- Completed recruitment filgotinib Ph2 in PsoA & AS
- '1972 target engagement in OA patients
- MOR106 results in AtD at AAD

IPF

- Announced ISABELA 1 & 2 Ph3 program for '1690

CF


- Completed Ph1 with 2nd triple combo
- Completed recruitment PELICAN ('2737)
- Approval for FALCON triple combo trial

Corporate

- Cash balance €1.1 billion on 31 March 2018



Ph3 program ISABELA 1&2



- 1500 IPF patients total, remain on standard of care throughout
- Global study with substantial US and EU component
- Primary endpoint: forced vital capacity (FVC) at 52 weeks
- Secondary: hospitalizations, mortality, quality of life, safety/tolerability

Robust Ph3 program expected to begin in H2 '18



FALCON

2 weeks

2 weeks

Part 1, dose A

Screening

Dual

Triple

Follow-up

homozygous

Part 2, dose B

Screening

Dual

Triple

Follow-up

heterozygous min

Dual

Triple

homozygous

- F508del patients, n=8 in each cohort
- Recruitment in Europe, incl. UK
- Primary endpoints: safety, tolerability, PK
- Secondary endpoints: sweat chloride, ppFEV%, CFQ-R



2018 outlook

LATE STAGE TRIAL INITIATIONS

ISABELA (~1690 in IPF)

Ph2 ~1205 in IPF

CF 1st triple (FALCON)

Ph2 2nd CF triple combo

Ph2 ~1972 in OA

Ph2 MOR106 in AtD

RESULTS EXPECTED IN H1

Filgotinib in PsoA
(EQUATOR)

CF PELICAN

Filgotinib interim UC
(SELECTION, go/no go)

Recruitment completed
for FINCH 1, FINCH 3

RESULTS EXPECTED IN H2


Filgotinib in RA
(FINCH 2)

Filgotinib in AS
(TORTUGA)

CF FALCON Part one



Cash & cash equivalents



Cash burn of €41M, cash of ≈€1.1B end of March

Notes:

- excluding tax incentive receivable from Belgian & French governments of €80.9 M in March '18



Key financials Q1 2018

Revenues: €44.8M (+ €4.9M)

- Includes €10.8M revenue recognition driven by IFRS15 adoption per 1 January 2018

Operating Costs: - €76.9M (- €25.8M)

- Increase driven by costs for mid & late stage development (Filgotinib, '1690, CF)

Net Result: - €37.3M (- €23.7M)

- Includes - €5.6M unrealized currency translation effect



Q1 2018 Results

- Q1 highlights/outlook

Onno van de Stolpe, CEO

Bart Filius, COO & CFO

- **Q & A**

Onno, Bart

Walid Abi-Saab, CMO

Piet Wigerinck, CSO